Here, the authors show the downregulation of CYP2C19 in NAFLD which supports developing personalized medicine approaches for drugs sensitive to metabolism by the CYP2C19 enzyme. This evidence concerns the gene CYP2C19 and metabolic dysfunction-associated steatotic liver disease.